GT860
/ Grit Biotechnology
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 02, 2026
GT860, a T-Cell-Targeted Lentiviral In Vivo Dual BCMA/GPRC5D CAR-T Candidate, Demonstrates Early Clinical Activity and Safety in Multiple Myeloma
(SITC 2026)
- No abstract available
CAR T-Cell Therapy • Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology
1 to 1
Of
1
Go to page
1